(NASDAQ: BEAM) Beam Therapeutics's forecast annual revenue growth rate of -11.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Beam Therapeutics's revenue in 2026 is $156,035,000.On average, 18 Wall Street analysts forecast BEAM's revenue for 2026 to be $5,398,019,948, with the lowest BEAM revenue forecast at $3,363,872,674, and the highest BEAM revenue forecast at $10,379,377,456. On average, 17 Wall Street analysts forecast BEAM's revenue for 2027 to be $6,361,590,575, with the lowest BEAM revenue forecast at $404,887,647, and the highest BEAM revenue forecast at $14,999,434,711.
In 2028, BEAM is forecast to generate $12,261,278,712 in revenue, with the lowest revenue forecast at $1,012,219,117 and the highest revenue forecast at $37,102,995,021.